Evidence map›Paper›PMID 9384581›Full record

ArticleThe EMBO journal1997

Control of B cell development by Ras-mediated activation of Raf.

B M Iritani, K A Forbush, M A Farrar, R M Perlmutter

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 146 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Kras Is Critical for B Cell Lymphopoiesis.Journal of immunology (Baltimore, Md. : 1950) · 2016
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

B M IritaniDepartment of Immunology, University of Washington, Seattle, WA 98195, USA.
K A Forbush
M A Farrar
R M Perlmutter
University of Washington · US

Funding

COMPARATIVE MEDICINET32RR007019 · NCRR · UNIVERSITY OF WASHINGTON · PI LIGGITT, HARRY DENNY · 1985 to 2006
$2.1M
ROLE OF P21 RAS IN B LYMPHOPOIESISK08AI001445 · NIAID · UNIVERSITY OF WASHINGTON · PI IRITANI, BRIAN M · 1997 to 2001
$241k
NCRR NIH HHS T32 RR07019NIAID NIH HHS K08 AI001445
6 · The paper itself

Abstract

Cell fate commitment in a variety of lineages requires signals conveyed via p21ras. To examine the role of p21ras in the development of B lymphocytes, we generated transgenic mice expressing a dominant-negative form of Ras in B lymphocyte progenitors, using a novel transcriptional element consisting of the Emu enhancer and the lck proximal promoter. Expression of dominant-negative Ras arrests B cell development at a very early stage, prior to formation of the pre-B cell receptor. Furthermore, an activated form of Raf expressed in the same experimental system could both drive the maturation of normal pro-B cells and rescue development of progenitors expressing dominant-negative Ras. Hence p21ras normally regulates early development of B lymphocytes by a mechanism that involves activation of the serine/threonine kinase Raf.

Indexed as

HematopoiesisAnimalsB-LymphocytesB-Lymphocyte SubsetsBone Marrow CellsCell DifferentiationCell LineageGene Expression RegulationHematopoietic Stem CellsLymphocyte DepletionMiceMice, TransgenicModels, BiologicalProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)Signal TransductionProto-Oncogene Proteins c-rafProto-Oncogene Proteins p21(ras)

Identifiers

PMID9384581
PMCPMC1170305
OpenAlexW2154546525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.